Based on our data, it is therefore possible that enhanced IL-6 production from CD8+ T cells may upregulate KLRC1 and suppress CD8+ T cell function in Neuro-PASC patients, which may increase Neuro-PASC symptom severity. This evidence concerns the gene KLRC1 and long COVID-19.